Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Wednesday

Atea Pharmaceuticals (NASDAQ:AVIR) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.49) per share for the quarter.

Atea Pharmaceuticals Stock Up 1.6 %

NASDAQ:AVIR opened at $3.14 on Tuesday. Atea Pharmaceuticals has a 1-year low of $2.75 and a 1-year high of $4.60. The firm has a market capitalization of $265.20 million, a price-to-earnings ratio of -1.52 and a beta of 0.19. The stock has a fifty day simple moving average of $3.19 and a 200 day simple moving average of $3.38.

Insider Activity at Atea Pharmaceuticals

In related news, Director Franklin M. Berger sold 359,606 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total value of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This trade represents a 44.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 17.80% of the stock is currently owned by corporate insiders.

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.